Boehringer Ingelheim is a research-driven company operating worldwide under two divisions: Human Pharmaceuticals and Animal Healthcare. In oncology, Boehringer Ingelheim is mainly focused on three areas: angiogenesis inhibition, EGFR inhibition and cell cycle kinase inhibition.
C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim GmbH, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany.
- In Dec 2020, Boehringer Ingelheim acquired NBE-Therapeutics in total transaction value of 1.18 billion euros, which also includes contingent clinical and regulatory milestones.
- In July 2019, Boehringer Ingelheim acquired AMAL Therapeutics in EUR 325 Mn. AMAL now operate as a subsidiary within Boehringer Ingelheim and remain at the campus of the University of Geneva in Switzerland.
- In Sep 2018, Boehringer Ingelheim acquired ViraTherapeutics GmbH, a biopharmaceutical company specializing in the development of oncolytic viral therapies in EUR 210 Mn.
Page 1 of 2
